Long-term outcome of stereotactic radiosurgery in oligodendroglioma
EANS Academy. Yang S. 09/25/19; 275557; EP07004
Prof. Dr. Seungyeob Yang
Prof. Dr. Seungyeob Yang

Access to this content is reserved for EANS members and attendees of this event. Click here to become an EANS member and gain your access to the full content of the EANS Academy


Abstract
Discussion Forum (0)
Rate & Comment (0)
Background: The treatment of recurrent oligodendrogliomas is challenging given the paucity of effective treatment options and the lack of well-designed studies on which to base therapy.
Objective: We assessed the role of stereotactic radiosurgery (SRS) performed as a salvage treatment in patients with recurrent oligodendrogliomas.
Methods: Between 1997 and 2014, a total of 44 consecutive patients with recurrent oligodendrogliomas were treated for 55 lesions with SRS. WHO grade 2 oligodendroglioma (OD), was diagnosed in 12 patients, and 32 patients were diagnosed with grade 3 anaplastic oligodendroglioma (AOD). The median time between primary diagnosis and SRS was 49.3 months for OD and 40.7 months for AOD. SRS was performed with a median target volume of 3.8 mL and a median margin dose of 17.0 Gy.
Results: Median overall survival after primary diagnosis was 176.9 months for patients with OD and 104.6 months for patients with AOD. Histologic grading was the strongest predictor of overall survival along with the extent of neurosurgical resection, malignant progression, and age at primary diagnosis. Median survival after SRS was 104.5 months for patients with OD and 26.4 months for patients with AOD. Median progression-free survival after SRS was 53.0 months for OD and 11.5 months for AOD. Histologic grading and presented with seizure at SRS were significant in influencing survival and progression-free survival after SRS.
Conclusion: SRS offers a considerable treatment option as a salvage treatment for patients with small lesions of recurrent OD/AOD.
Background: The treatment of recurrent oligodendrogliomas is challenging given the paucity of effective treatment options and the lack of well-designed studies on which to base therapy.
Objective: We assessed the role of stereotactic radiosurgery (SRS) performed as a salvage treatment in patients with recurrent oligodendrogliomas.
Methods: Between 1997 and 2014, a total of 44 consecutive patients with recurrent oligodendrogliomas were treated for 55 lesions with SRS. WHO grade 2 oligodendroglioma (OD), was diagnosed in 12 patients, and 32 patients were diagnosed with grade 3 anaplastic oligodendroglioma (AOD). The median time between primary diagnosis and SRS was 49.3 months for OD and 40.7 months for AOD. SRS was performed with a median target volume of 3.8 mL and a median margin dose of 17.0 Gy.
Results: Median overall survival after primary diagnosis was 176.9 months for patients with OD and 104.6 months for patients with AOD. Histologic grading was the strongest predictor of overall survival along with the extent of neurosurgical resection, malignant progression, and age at primary diagnosis. Median survival after SRS was 104.5 months for patients with OD and 26.4 months for patients with AOD. Median progression-free survival after SRS was 53.0 months for OD and 11.5 months for AOD. Histologic grading and presented with seizure at SRS were significant in influencing survival and progression-free survival after SRS.
Conclusion: SRS offers a considerable treatment option as a salvage treatment for patients with small lesions of recurrent OD/AOD.
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies